Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
Allogene Therapeutics reports 2019 executive compensation
By ExecPay News
Published: April 23, 2020
Allogene Therapeutics reported fiscal year 2019 executive compensation information on April 23, 2020.
In 2019, four executives at Allogene Therapeutics received on average a compensation package of $6.3M, a 21% increase compared to previous year.
Average pay of disclosed executives at Allogene Therapeutics
David Chang, Chief Executive Officer, received $11M in total, which decreased by 13% compared to 2018. 48% of Chang's compensation, or $5.3M, was in option awards. Chang also received $363K in non-equity incentive plan, $600K in salary, $4.7M in stock awards, as well as $250K in other compensation.
Rafael Amado, Chief Medical Officer, received a compensation package of $7.5M. 57% of the compensation package, or $4.2M, was in stock awards.
Eric Schmidt, Chief Financial Officer, earned $3.5M in 2019, a 34% increase compared to previous year.
Alison Moore, Chief Technical Officer, received $3.1M in 2019, which increases by 70% compared to 2018.
Related executives
You may also like
Source: SEC filing on April 23, 2020.